Literature DB >> 20865198

Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships.

Timothy R Rudd1, Katarzyna A Uniewicz, Alessandro Ori, Scott E Guimond, Mark A Skidmore, Davide Gaudesi, Ruoyan Xu, Jeremy E Turnbull, Marco Guerrini, Giangiacomo Torri, Giuliano Siligardi, Mark C Wilkinson, David G Fernig, Edwin A Yates.   

Abstract

The activities of heparan sulfate (HS) and heparin do not correlate simply with sulfation levels or sequence. The alternative hypothesis, that appropriate charge and conformational characteristics for protein binding and activity can be provided by other sequences in heparan sulfate and, possibly, also in unrelated sulfated polysaccharides, is explored. Differential scanning fluorimetry was used to measure the thermostabilisation bestowed by modified heparin polysaccharides (proxies for heparan sulfate) on fibroblast growth factor-1 (FGF-1) and fibroblast growth factor-2 (FGF-2), prototypical heparan sulfate-binding proteins, revealing varied abilities and primary sequence-activity redundancy. The effect of substitution pattern on the heparin/heparan sulfate backbone was explored using principal component analysis of (13)C NMR chemical shift data for homogeneously modified heparin polysaccharides revealing complex conformational effects. No simple relationship emerged between these polysaccharides, with their distinct charge distributions and geometries, and their ability to signal. Other, structurally unrelated sulfated polysaccharides were also able to support signalling. These influenced FGF stabilisation in a similar manner to the HS analogues and provided analogous cell signalling activity. For FGF-1, but not FGF-2, signaling correlated strongly with protein stabilisation and circular dichroism spectroscopy demonstrated that some non-HS polysaccharides invoked comparable secondary structural changes to those induced by heparin. Active conformations can readily be found in several heparin derivatives, as well as among non-HS polysaccharides, which comprise unrelated primary sequences, confirming the hypothesis and implying that the level of unique information contained in HS sequences may be much lower than previously thought.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865198     DOI: 10.1039/c0ob00246a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  11 in total

1.  Heparan Sulfate Regrowth Profiles Under Laminar Shear Flow Following Enzymatic Degradation.

Authors:  Kristina M Giantsos-Adams; Andrew Jia-An Koo; Sukhyun Song; Jiro Sakai; Jagadish Sankaran; Jennifer H Shin; Guillermo Garcia-Cardena; C Forbes Dewey
Journal:  Cell Mol Bioeng       Date:  2013-02-20       Impact factor: 2.321

2.  Diversification of the structural determinants of fibroblast growth factor-heparin interactions: implications for binding specificity.

Authors:  Ruoyan Xu; Alessandro Ori; Timothy R Rudd; Katarzyna A Uniewicz; Yassir A Ahmed; Scott E Guimond; Mark A Skidmore; Giuliano Siligardi; Edwin A Yates; David G Fernig
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 3.  Heparan sulfate and heparin interactions with proteins.

Authors:  Maria C Z Meneghetti; Ashley J Hughes; Timothy R Rudd; Helena B Nader; Andrew K Powell; Edwin A Yates; Marcelo A Lima
Journal:  J R Soc Interface       Date:  2015-09-06       Impact factor: 4.118

4.  Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate.

Authors:  Laurence Duchesne; Vivien Octeau; Rachel N Bearon; Alison Beckett; Ian A Prior; Brahim Lounis; David G Fernig
Journal:  PLoS Biol       Date:  2012-07-17       Impact factor: 8.029

Review 5.  Heparan sulphate, its derivatives and analogues share structural characteristics that can be exploited, particularly in inhibiting microbial attachment.

Authors:  T R Rudd; A Hughes; J Holman; V Solari; E de Oliveira Ferreira; R M Cavalcante Pilotto Domingues; E A Yates
Journal:  Braz J Med Biol Res       Date:  2012-04-05       Impact factor: 2.590

6.  Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis.

Authors:  Arthur A Decarlo; Maria Belousova; April L Ellis; Donald Petersen; Hernan Grenett; Patrick Hardigan; Robert O'Grady; Megan Lord; John M Whitelock
Journal:  BMC Biotechnol       Date:  2012-09-11       Impact factor: 2.563

7.  The crystal structure of fibroblast growth factor 18 (FGF18).

Authors:  Alan Brown; Lucy E Adam; Tom L Blundell
Journal:  Protein Cell       Date:  2014-05       Impact factor: 14.870

8.  Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.

Authors:  Chiara Foglieni; Katiuscia Pagano; Marco Lessi; Antonella Bugatti; Elisabetta Moroni; Denise Pinessi; Andrea Resovi; Domenico Ribatti; Sabrina Bertini; Laura Ragona; Fabio Bellina; Marco Rusnati; Giorgio Colombo; Giulia Taraboletti
Journal:  Sci Rep       Date:  2016-03-22       Impact factor: 4.379

Review 9.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02

10.  Heparin binding preference and structures in the fibroblast growth factor family parallel their evolutionary diversification.

Authors:  Yong Li; Changye Sun; Edwin A Yates; Chao Jiang; Mark C Wilkinson; David G Fernig
Journal:  Open Biol       Date:  2016-03       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.